BioLife Solutions first quarter revenue is $611,000 for March 31, 2011

BioLife Solutions, Inc. (OTCBB: BLFS), a leading developer and manufacturer of clinical grade biopreservation media products for cells and tissues, today announced preliminary revenue of $611,000 for its first quarter ended March 31, 2011. This represents 6% sequential growth over the fourth quarter of 2010 and 19 percent growth from the first quarter of 2010.  

Mike Rice, Chairman and CEO, commented on the Company's revenue by stating, "We're pleased with the progress we made last year and in the first quarter of 2011 in generating revenue growth to reduce our operating loss as we strive to reach profitability.  First quarter revenue was a mix of orders shipped to new accounts, including a new contract manufacturing customer, and strong orders from our numerous existing customers in the developing regenerative medicine market, where our proprietary biopreservation media products are used to extend stability and increase viability of biologics used in cell therapy and tissue-engineering applications.  We also realized strong growth in our indirect distribution channel, with year-to-date revenue already more than 50% of our full year 2010 total.  Our partners continue to build awareness of the value of our best-in-class biopreservation media products, and their efforts are resulting in increasing orders from their end customers."

MedMarket Diligence, LLC, estimates that the current worldwide market for regenerative medicine products and services is growing at 20 percent annually.  Rice commented, "We expect pre-formulated biopreservation media products such as our HypoThermosol® and CryoStor® to continue to displace 'home-brew' cocktails, creating demand for clinical grade preservation reagents that will grow at greater than the overall end market rate.  We estimate that in-house formulated 'home-brew' storage and freeze media comprise 80% of the market." 

The Company's financial statements for the first quarter of 2011 will be included in the Company's 10-Q quarterly report, which it expects to file with the U.S. Securities and Exchange Commission on or before May 16, 2011.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Balance on one leg may be the best indicator of neuromuscular aging, new study suggests